Prognostic and predictive biomarkers in early stage non-small cell lung cancer: tumor based approaches including gene signatures

被引：51

作者：

Carnio, Simona ^{[1
]}

Novello, Silvia ^{[1
]}

Papotti, Mauro ^{[1
]}

Loiacono, Marco ^{[1
]}

Scagliotti, Giorgio Vittorio ^{[1
]}

机构：

[1] Univ Torino, Dept Oncol, Turin, Italy

来源：

TRANSLATIONAL LUNG CANCER RESEARCH | 2013年 / 2卷 / 05期

关键词：

Prognostic and predictive biomarkers; early stages; non-small cell lung cancer (NSCLC); gene signatures;

D O I：

10.3978/j.issn.2218-6751.2013.10.05

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

In early stage non-small cell lung cancer (NSCLC) large randomized trials have demonstrated that in patients with radically resected disease adjuvant chemotherapy improves 5-year survival rates. However, a customization of systemic treatment is needed to avoid treatments in patients cured by surgery alone or to justify the use of adjuvant chemotherapy in high risk patients, including those in stage IA. Recently, the possibility of identifying prognostic and predictive factors related to the genetic signatures of the tumor that could affect adjuvant and neo-adjuvant treatment choices for resectable non-small cell lung cancer (NSCLC) has been of interest. This review summarizes the current status and future opportunities for clinical application of genotyping and genomic tests in early NSCLC.

引用

页码：372 / 381

页数：10

共 88 条

[51] DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy [J].

Olaussen, Ken A. ;

Dunant, Ariane ;

Fouret, Pierre ;

Brambilla, Elisabeth ;

Andre, Fabrice ;

Haddad, Vincent ;

Taranchon, Estelle ;

Filipits, Martin ;

Pirker, Robert ;

Popper, Helmut H. ;

Stahel, Rolf ;

Sabatier, Laure ;

Pignon, Jean-Pierre ;

Tursz, Thomas ;

Le Chevalier, Thierry ;

Soria, Jean-Charles .

NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (10) :983-991

[52] Immunocytochemical markers in stage I lung cancer: Relevance to prognosis [J].

Pastorino, U ;

Andreola, S ;

Tagliabue, E ;

Pezzella, F ;

Incarbone, M ;

Sozzi, G ;

Buyse, M ;

Menard, S ;

Pierotti, M ;

Rilke, F .

JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (08) :2858-2865

[53] Cisplatin benefit is predicted by immunohistochemical analysis of DNA repair proteins in squamous cell carcinoma but not adenocarcinoma: theranostic modeling by NSCLC constituent histological subclasses [J].

Pierceall, W. E. ;

Olaussen, K. A. ;

Rousseau, V. ;

Brambilla, E. ;

Sprott, K. M. ;

Andre, F. ;

Pignon, J-P. ;

Le Chevalier, T. ;

Pirker, R. ;

Jiang, C. ;

Filipits, M. ;

Chen, Y. ;

Kutok, J. L. ;

Weaver, D. T. ;

Ward, B. E. ;

Soria, J-C. .

ANNALS OF ONCOLOGY, 2012, 23 (09) :2245-2252

[54] Lung Adjuvant Cisplatin Evaluation: A pooled analysis by the LACE collaborative group [J].

Pignon, Jean-Pierre ;

Tribodet, Helene ;

Scagliotti, Giorgio V. ;

Douillard, Jean-Yves ;

Shepherd, Frances A. ;

Stephens, Richard J. ;

Dunant, Ariane ;

Torri, Valter ;

Rosell, Rafael ;

Seymour, Lesley ;

Spiro, Stephen G. ;

Rolland, Estelle ;

Fossati, Roldano ;

Aubert, Delphine ;

Ding, Keyue ;

Waller, David ;

Le Chevalier, Thierry .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (21) :3552-3559

[55] Cancer care Ontario and American society of clinical oncology adjuvant chemotherapy and adjuvant radiation therapy for stages I-IIIA resectable non-small-cell lung cancer guideline [J].

Pisters, Katherine M. W. ;

Evans, William K. ;

Azzoli, Christopher G. ;

Kris, Mark G. ;

Smith, Christopher A. ;

Desch, Christopher E. ;

Somerfield, Mark R. ;

Brouwers, Melissa C. ;

Darling, Gail ;

Ellis, Peter M. ;

Gaspar, Laurie E. ;

Pass, Harvey I. ;

Spigel, David R. ;

Strawn, John R. ;

Ung, Yee C. ;

Shepherd, Frances A. .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (34) :5506-5518

[56] Prognostic value of class III b-tubulin (TUBB3) in operable non-small cell lung cancer (NSCLC) and predictive value for adjuvant cisplatin-based chemotherapy (CT): A validation study on three randomized trials [J].

Reiman, T. ;

Seve, P. ;

Vataire, A. ;

Dunant, A. ;

Rosell, R. ;

Graziano, S. ;

Seymour, L. ;

Pirker, R. ;

Lai, R. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)

[57]

REKHTMAN N, 2008, J CLIN ONCOL S, V26

[58] Randomized Phase III Trial of Gemcitabine-Based Chemotherapy With In Situ RRM1 and ERCC1 Protein Levels for Response Prediction in Non-Small-Cell Lung Cancer [J].

Reynolds, Craig ;

Obasaju, Coleman ;

Schell, Michael J. ;

Li, Xueli ;

Zheng, Zhong ;

Boulware, David ;

Caton, John R. ;

DeMarco, Linda C. ;

O'Rourke, Mark A. ;

Wright, Gail Shaw ;

Boehm, Kristi A. ;

Asmar, Lina ;

Bromund, Jane ;

Peng, Guangbin ;

Monberg, Matthew J. ;

Bepler, Gerold .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (34) :5808-5815

[59] Gene expression as a predictive marker of outcome in stage IIB-IIIA-IIIB non-small cell lung cancer after induction gemcitabine-based chemotherapy followed by resectional surgery [J].

Rosell, R ;

Felip, E ;

Taron, M ;

Majo, J ;

Mendez, P ;

Sanchez-Ronco, M ;

Queralt, C ;

Sanchez, JJ ;

Maestre, J .

CLINICAL CANCER RESEARCH, 2004, 10 (12) :4215S-4219S

[60] Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients [J].

Rosell, R ;

Danenberg, KD ;

Alberola, V ;

Bepler, G ;

Sanchez, JJ ;

Camps, C ;

Provencio, M ;

Isla, D ;

Taron, M ;

Diz, P ;

Artal, A .

CLINICAL CANCER RESEARCH, 2004, 10 (04) :1318-1325

← 1 2 3 4 5 6 7 8 9 →